stockportfolio.pro
AngioDynamics, Inc. (ANGO)
Healthcare · Medical Instruments & Supplies · NasdaqGS
AngioDynamics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $353.89M | $269.79M | $261.65M | $270.63M | $264.16M | $291.01M | $316.22M | $338.75M | $303.91M | $292.50M |
| Gross profit | $174.32M | $143.95M | $143.86M | $156.00M | $150.27M | $156.79M | $165.73M | $174.25M | $154.70M | $157.71M |
| Net income | $-43.59M | $5.01M | $16.34M | $61.34M | $-166.79M | $-31.55M | $-26.55M | $-52.44M | $-184.35M | $-33.99M |
| Net margin | -12.3% | 1.9% | 6.2% | 22.7% | -63.1% | -10.8% | -8.4% | -15.5% | -60.7% | -11.6% |
Source: AngioDynamics, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of AngioDynamics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ANGO in your portfolio →
AngioDynamics, Inc. financial history by metric
About AngioDynamics, Inc.
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
AngioDynamics, Inc. — frequently asked questions
What is AngioDynamics, Inc.'s revenue?
AngioDynamics, Inc. (ANGO) reported revenue of $292.50M for fiscal year 2025, down 3.8% from the prior year, according to its SEC filings.
Is AngioDynamics, Inc. profitable?
No — ANGO reported a net loss of $-33.99M in fiscal 2025.
What is ANGO's P/E ratio?
AngioDynamics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is AngioDynamics, Inc. growing?
ANGO's revenue grew at roughly 2.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does AngioDynamics, Inc. have?
As of fiscal year 2025, ANGO carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is AngioDynamics, Inc.'s gross margin?
ANGO's gross margin was 53.9% in fiscal 2025 — gross profit of $157.71M on revenue of $292.50M.
What is AngioDynamics, Inc.'s market cap?
AngioDynamics, Inc. (ANGO) has a market capitalization of about $495.41M, based on the latest data in our nightly-refreshed cache.
When does AngioDynamics, Inc.'s fiscal year end?
ANGO's fiscal year ends in May. Its most recent annual filing covers the fiscal year ending 2025-05-31.
Where does this data come from?
All figures are computed from AngioDynamics, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.